XNK partners with Swedish hospital to develop AML therapy
XNK Therapeutics adds another research partner to evaluate XNK’s natural killer cell therapy candidate in acute myeloid leukaemia.
XNK Therapeutics adds another research partner to evaluate XNK’s natural killer cell therapy candidate in acute myeloid leukaemia.
What's Your Reaction?
